Lead product candidate, PRO 140, is a viral-entry inhibitor that works by blocking the entry of HIV/AIDS to healthy cells by masking CCR5 receptor Completion of Biological License Application (BLA) for potential approval in combination HIV therapy expected in Q1 2019 CytoDyn received approval to increase dosing of PRO 140 in its phase 3 adaptive […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.